Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds

Hyekyung Yang1, Wei-na Cong1, Jeong Seon Yoon2 & Josephine M. Egan1

1Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, Maryland
2Laboratory of Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, Maryland

Abstract

Vismodegib, a highly selective inhibitor of hedgehog (Hh) pathway, is an approved treatment for basal-cell carcinoma. Patients on treatment with vismodegib often report profound alterations in taste sensation. The cellular mechanisms underlying the alterations have not been studied. Sonic Hh (Shh) signaling is required for cell growth and differentiation. In taste buds, Shh is exclusively expressed in type IV taste cells, which are undifferentiated basal cells and the precursors of the three types of taste sensing cells. Thus, we investigated if vismodegib has an inhibitory effect on taste cell turnover because of its known effects on Hh signaling. We gavaged C57BL/6J male mice daily with either vehicle or 30 mg/kg vismodegib for 15 weeks. The gustatory behavior and immunohistochemical profile of taste cells were examined. Vismodegib-treated mice showed decreased growth rate and behavioral responsivity to sweet and bitter stimuli, compared to vehicle-treated mice. We found that vismodegib-treated mice had significant reductions in taste bud size and numbers of taste cells per taste bud. Additionally, vismodegib treatment resulted in decreased numbers of Ki67- and Shh-expressing cells in taste buds. The numbers of phospholipase Cb2- and α-gustducin-expressing cells, which contain biochemical machinery for sweet and bitter sensing, were reduced in vismodegib-treated mice. Furthermore, vismodegib treatment resulted in reduction in numbers of T1R3, glucagon-like peptide-1, and glucagon-expressing cells, which are known to modulate sweet taste sensitivity. These results suggest that inhibition of Shh signaling by vismodegib treatment directly results in alteration of taste due to local effects in taste buds.

Introduction

Basal-cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States, with an annual incidence rate of approximately 1.5% that continues to increase [1]. BCC is associated with mutations in components of the hedgehog (Hh) signaling pathway. Hh is a key regulator of cell growth and differentiation during development and controls epithelial and mesenchymal interactions in many tissues during embryogenesis. Hh binds to its receptor patched homologue 1 (PTCH1) and prevents PTCH1-mediated inhibition of signaling by smothened homologue (SMO). Signaling by SMO results in the activation of transcription factors encoded by GLI family zinc finger (GLI) and consequent induction of Hh target genes, including GLI1 [2]. Basal-cell tumors have mutations in the Hh signaling pathway that inactivate PTCH1 (loss-of-function mutation) or, less commonly, constitutively activate SMO (gain-of-function mutation) [3–5]. These mutations cause constitutive activation of Hh signaling that may result in uncontrolled proliferation of basal cells. Thus, blocking the Hh pathway is a therapeutic option in patients with BCC [6, 7].

Vismodegib (Erivedge®, Genentech-Curis) is the first oral medicine approved by the US Food and Drug Administration for the treatment of adults with advanced BCC (refer to both locally advanced and distantly metastatic BCCs) that has recurred after surgery or cannot be resected or irradiated. It selectively inhibits SMO, a central mediator of Hh signaling [8–12].
Intriguingly, patients on treatment with vismodegib often report alterations in taste sensation (dysgeusia) [9–11]. In a trial conducted by Von Hoff et al., dysgeusia as a grade 2 adverse event occurred in six percent of patients [9]. Sekulic et al. reported dysgeusia in 51% of recipients, which was mild to moderate in severity [10]. Dysgeusia is also a class effect because it has been reported to occur with other SMO inhibitors, such as sonidegib [13–15]: the therefore is likely to be mechanism-related [16–18]. However, to date, there is no evidence for direct effects of systemic vismodegib administration in taste buds.

Taste cells are organized within onion-shaped taste buds that reside in three types of papillae in the tongue; fungiform, foliate, and circumvallate papillae. Fungiform and foliate papillae are present on the anterior two-thirds and the posterior sides of the tongue, respectively, while circumvallate papillae, containing the greatest numbers of taste buds, are located under the uvula [19]. The taste cells contain the signaling molecules to detect all five prototypic types of taste: sweet, umami, bitter, salty, and sour [20]. Taste cells are maintained by continuous cell renewal and the average taste cell lifespan is approximately 10–16 days [21, 22]. Taste cells are categorized into four types (types I–IV) [20]. Type I cells have chemosensing (for salt taste) and supporting functions [23]. Type II cells are primary chemosensing that contain the molecules for detecting sweet, umami, and bitter tastes: x-gustducin, T1 receptors (T1R) that detect sweet, including natural sweet tasting food, sweeteners and umami, and T2R that detect bitter [24, 25]. Type III cells have direct afferent contacts, considered to be the neuronal output cells, and they contain many neurotransmitters as well as the molecular machinery for detecting sour taste [26, 27]. Type IV cells are nonpolarized, undifferentiated cells located at the base of taste buds, in which sonic Hh (Shh) is exclusively expressed. They are the precursors of the remaining three types (types I–III) of taste cells in taste buds [28]. Additionally, taste cells contain many hormones, cholecystokinin, glucagon, glucagon-like peptide-1 (GLP-1), vasoactive intestinal peptide, neuropeptide Y, and ghrelin, that modulate the perception of prototypic tastes [29–32].

In addition to its role in proliferation of type IV cells, Shh plays a critical role in development and patterning of taste papillae in rodents [33]. The steroidal alkaloid, cyclopamine, which is a selective disruptor of Shh signaling pathway, or a Shh-blocking antibody altered fungiform papilla induction and distribution in embryonic rat tongue cultures [33]. Here we hypothesized that vismodegib inhibits Shh signaling in taste cells, leading to disruption of taste cell turnover, that results, over time, in taste disturbance. We show that vismodegib treatment causes alteration in taste bud morphology and expression of taste sensing machinery in taste cells. Our results suggest that inhibition of Shh signaling by vismodegib treatment directly results in alteration of taste due to local effects in taste buds.

Materials and Methods

Animal and tissue processing

All animal care and experimental procedures followed U.S. National Institutes of Health guidelines and were approved by the Animal Care and Use Committee of the National Institute on Aging. Male C57BL/6j mice (Jackson Laboratory, Bar Harbor, ME) were administered by daily oral gavage of 30 mg/kg vismodegib (LC Laboratories, Woburn, MA) in 0.5% methylcellulose and 0.2% Tween 80 (MCT) [34]. Animals of both vehicle and vismodegib groups were euthanized after 15 weeks of treatment using isoflurane overdose and tongues were collected from each animal. The length of the study was to allow for at least four taste cell turnovers. Tongues were fixed in 10% neutral-buffered formalin (Sigma-Aldrich, St Louis, MO) for 1 h and then cryoprotected with 20% sucrose in 0.1 mol/L phosphate buffer overnight at 4°C. Serial sections (8–10 μm thickness) were cut through circumvallate papillae using a cryostat (HM 500M, MICRON, GmbH, Germany). In order to obtain a systematic appreciation without bias of the entire papillae, each papilla was sectioned and every 10th section was saved onto a slide. As taste buds are approximately 80–100 μm in length, sampling every 10th section ensured that no two sections were from the same taste bud.

Taste behavioral tests

Two-bottle taste test was carried out as described previously [35, 36]. All tastants were prepared with purified water from the National Institute on Aging animal facility and reagent-grade chemicals were presented to the animals at room temperature. Two different testing protocols were used: one for normally preferred stimulus (sucrose; Sigma-Aldrich) and one for normally avoided stimulus (denatonium benzoate, DB; Sigma-Aldrich). Preference was characterized by calculating the ratio of tastant intake to water intake over 24 h.

RNA isolation and real-time PCR of taste buds

Real-time RT-PCR experiments were performed on total RNA isolated from taste buds of foliate papillae and non-taste epithelial tissue devoid of taste cells as described previously [36]. The reverse-transcriptase reactions were...
performed using qScript cDNA SuperMix (Quanta Bio-
sciences, Gaithersburg, MD). Reverse-transcribed cDNAs
were amplified using PerfeCTa SYBR Green SuperMix,
UNG (Quanta Biosciences). Primer sequences were
described in Table 1. The data were normalized to glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) mRNA.

Immunohistochemistry
Following antigen retrieval with 10 mmol/L sodium cit-
rate buffer (pH 6.0) at 98°C for 20 min, immunofluores-
cence analyses were performed as described previously
[37]. Sources and dilutions of the applied primary anti-
bodies are listed in Table 2. 4',6-diamidino-2-phenylind-
dole (DAPI, 1:5000 dilution; Sigma-Aldrich) was used for
nuclear staining. No fluorescent staining was observed in
any sections when the primary antibodies were omitted.

Quantification of immunoreactive taste cells
Mouse taste bud images were collected using an LSM-710
confocal microscope (Carl Zeiss MicroImaging, Thorn-
wood, NY) in single planes. Approximately 100–120 taste
buds per group were analyzed as described previously [31,
36, 37]. Cells were scored as immunopositive only if a
nuclear profile was present within the cell. The total num-
ber of cells in the section was determined by counting the
number of DAPI-stained nuclei present in each taste bud.
Finally, the percentage of immunoreactive taste cells was
calculated by dividing the number of immunopositive
taste cells by the total number of the taste cells in each
taste bud. Both image capture and data analysis was per-
formed by trained researchers who were blind to the
experimental and control conditions.

Quantification of taste bud size and taste
cell numbers per taste bud
Taste bud sizes were calculated in accordance with our previ-
ous methods [37]. In brief, the perimeters of the taste bud
from every 10th section were outlined and the corresponding
area was computed by the Zeiss LSM Image Browser soft-
ware (Carl Zeiss MicroImaging). Simultaneously, 20 taste
buds were randomly selected at different regions of each ton-
gue to count the number of cells in a single taste bud, where
one nucleus corresponded to one cell on the section.

Statistical analyses
All data represent means ± SEM from at least three inde-
pendent experimental replicates. Error bars on graphs
represent the ±95% confidence interval. One-way analysis
of variance (ANOVA) with the Bonferroni post-hoc test
was performed by GraphPad Prism 6.0 (GraphPad Soft-
ware, Inc., La Jolla, CA) as appropriate. P < 0.05 was
considered statistically significant throughout the study.

Results
Vismodegib attenuates body growth rate
and taste responsivity
In patients received vismodegib for treatment of BCC,
weight loss and taste disturbance were commonly reported
[10, 11]. We monitored the body weight of vehicle- and
vismodegib-treated mice during treatment for 15 weeks.
After 4–5 weeks of treatment, the body weights of the two
groups began to diverge and by 10 weeks of treatment, the
weights of vismodegib-treated mice were significantly dif-
ferent from vehicle-treated mice (Fig. 1A) and continued
to diverge. By 15 weeks, vismodegib-treated mice were 9%
lighter compared with vehicle-treated mice (P < 0.05).

Next, we investigated potential differences in their taste
perception. We tested the ability of both vehicle- and
vismodegib-treated mice to detect sweet (sucrose) and bitter
(DB, Fig. 1B) by two-bottle taste test. We found that vis-
modegib-treated animals showed trends of reduced taste
responsivity compared with vehicle-treated animals for
sucrose and DB (Fig. 1B; sucrose [top], P = 0.371; DB
[bottom], P = 0.296).
To determine whether vismodegib treatment suppresses Hh signaling in taste buds, we measured Gli1 transcription, which is a downstream target and transcription factor of Hh signaling pathway, in foliate papillae from vehicle- and vismodegib-treated animals. As expected, vismodegib significantly decreased the Hh signaling, as shown by a 40% decrease in Gli1 mRNA expression (Fig. 2).

Vismodegib alters taste bud size and number of taste cells per taste bud

To investigate whether the alteration in taste behavior and reduction in Hh signaling in taste buds from vismodegib-treated mice causes any alterations in taste bud morphology, we determined taste bud size and taste cell numbers per taste bud. We found that vismodegib-treated mice had significantly smaller taste buds (Fig. 3A), compared to vehicle-treated mice and this was likely because there was a significant reduction in the numbers of taste cells within each taste bud in vismodegib-treated mice (Fig. 3B).

Vismodegib alters potential of taste cell renewal in taste bud

Adult taste buds are maintained by differentiation of type IV cells to any of the other three taste cell types [38, 39]. To investigate whether the alteration in taste bud size and taste cell numbers is associated with delayed cell renewal, we examined cell proliferation in taste buds by labeling with Ki67 as a marker of cell turnover. We found that vismodegib treatment resulted in decreased numbers of Ki67-positive cells in taste bud (Fig. 4A). Additionally, there was a significant reduction in the number of Shh-expressing taste cells in vismodegib-treated animals compared with vehicle-treated animals (Fig. 4B).

Vismodegib alters taste sensing machinery and hormone expression in taste buds

As we found alteration in taste modality and total taste cell number, we next investigated the expression of multiple taste-modulatory factors in the taste cells of vehicle- and vismodegib-treated mice. α-Gustducin and phospholipase Cβ2 (PLCβ2) are essential chemosensing molecules in type II cells [24, 40–42]. α-Gustducin is the alpha subunit of the G-protein coupled to T1R and T2R
and α-gustducin null mice have significantly reduced behavioral and/or nerve responses to bitter, sweet, and umami stimuli [40, 43]. PLCβ2 is a key enzyme that is necessary for sweet-, umami-, and bitter-signal transduction. It is activated by βγ subunits of trimeric G proteins and it produces the 2-sec messengers, diacylglycerol, and inositol triphosphate, that connect taste receptor signals to downstream components of taste signal transduction ultimately to the brain [44]. We found that the numbers of α-gustducin- and PLCβ2-expressing cells were significantly reduced in vismodegib-treated animals compared with vehicle-treated mice (Fig. 5A and B). T1R3 (the G protein-coupled receptor necessary for detecting sweet and umami) null mice have the greatly reduced gustatory nerve and behavioral responses to sugars and artificial sweeteners [45]. We also found a significant reduction in the number of T1R3 immunoreactive cells in vismodegib-treated mice compared with vehicle-treated mice (Fig. 5C). We previously reported that GLP-1 and glucagon are expressed in taste cells where they enhance sweet taste responsivity [30, 46]. As shown in Figure 5D and E, there were reductions in the numbers of GLP-1- and glucagon-expressing cells as well as severely reduced GLP-1 and glucagon expression in vismodegib-treated animals compared with vehicle-treated animals.

**Discussion**

In this study, we investigated the effects of vismodegib, given orally to mice so as to mimic how it is administered to patients, in order to provide a potential explanation for the distortion in taste perception that is reported to occur in up to 55% of patients taking vismodegib for BCC. In mice, oral vismodegib administration leads to decreased body weight, and reduction in the number of cells expressing sweet taste receptors and downstream...
signaling molecules. We also found a lower expression of hormones known to enhance sweet taste as well as a decrease in the numbers of cells expressing those hormones.

Taste cells have a limited lifespan, die by apoptosis and so must undergo replacement throughout life. Developmentally, they arise from Shh-expressing cells that have the properties of taste cell progenitors and that undergo continuous division [38, 39]. Either innervating nerves supply signals to the type IV cells to become specific ‘newborn’ taste cells or they are fate-committed cells that require signals from the nerves to become specifically terminally differentiated taste cells [47]. These conclusions regarding neuronal input to taste bud maintenance derive from elegant experiments showing that denervation leads to disappearance of taste buds in the first few weeks after denervation followed by their reappearance once nerve regrowth has occurred [38]. It is also known that the type IV cells continuously undergo replication, as shown by Ki67, Shh and BrdU staining, so as to maintain

Figure 5. Expression of taste-modulating factors, a-gustducin (A), PLCβ2 (B), T1R3 (C), GLP-1 (D), and glucagon (E), in circumvallate papillae taste cells of vehicle- and vismodegib-treated mice. The histograms associated with each taste bud represent the percentage of immunoreactive taste cells containing each marker out of the total number of taste cells in each taste bud. All scale bars are 20 μm. Blue is DAPI nuclear stain. Value are expressed as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle-treated group.
sufficient precursor cell numbers continuously available to receive neuronal signals [38, 39]. It appears that vismodegib causes a decrease in the numbers of type IV cells because of deceleration of their replication rate, as shown by a significant reduction in the number of cells positive for Ki67, a well-accepted marker of replicating cells, and Shh. And this, in turn, leads to a decrease in the numbers of cells capable of being in the ‘on’ mode so as to differentiate, on an as-needed basis, in order to refill the population of cells that undergoes death. The cells most affected by the reduction in Shh-positive numbers are the sweet taste receptor T1R3-expressing cells, in addition to GLP-1-and glucagon-containing cells; the receptor is necessary for sweet tasting and the hormones, both active fragments of the proglucagon molecule, locally enhance sweet taste responsivity.

Vismodegib is a competitive antagonist of SMO, a part of the Hh signaling pathway. Total SMO inhibition causes the transcription factor GLI1 to remain inactive, that in turn depresses expression of genes regulated by the Hh signaling pathway [2]. In the present study GLI1 expression in taste buds was decreased, but not fully inhibited, by vismodegib treatment in the mice. Even though not fully suppressed, this still resulted in a severe phenotype in taste cells. Therefore, complete suppression is not required to cause alterations in taste molecules.

To our knowledge, the current study is the first to demonstrate that vismodegib affects taste cell turnover and taste functional integrity. These findings provide an explanation for the changes in vismodegib-induced human taste perception because vismodegib most likely results in similar alterations in human taste buds.

Conflicts of Interest

None declared.

References

1. Wu, S., J. Han, W. Q. Li, T. Li, and A. A. Qureshi. 2013. Basal-cell carcinoma incidence and associated risk factors in US women and men. Am. J. Epidemiol. 178:890–897.
2. Ingham, P. W., and A. P. McMahon. 2001. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15:3059–3097.
3. Hahn, H., C. Wicking, P. G. Zaphiropoulos, M. R. Gailani, S. Shanley, A. Chidambaram, et al. 1996. Mutations of the human homolog of Drosophila patched in the nenoid basal cell carcinoma syndrome. Cell 85:841–851.
4. Aszterbaum, M., A. Rothman, R. L. Johnson, M. Fisher, J. Xie, J. M. Bonifas, et al. 1998. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110:885–888.
5. Xie, J., M. Murone, S. M. Luoh, A. Ryan, Q. Gu, C. Zhang, et al. 1998. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391:90–92.
6. Rubin, L. L., and F. J. de Sauvage. 2006. Targeting the hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5:1026–1033.
7. Epstein, E. H. 2008. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 8:743–754.
8. Robarge, K. D., S. A. Brunton, G. M. Castanedo, Y. Cui, M. S. Dina, R. Goldsmith, et al. 2009. GDC-0449: A potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19:5576–5581.
9. Von Hoff, D. D., P. M. LoRusso, C. M. Rudin, J. C. Reddy, R. L. Yauch, R. Tíbes, et al. 2009. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361:1164–1172.
10. Sekulic, A., M. R. Migden, A. E. Oro, L. Dirix, K. D. Lewis, J. D. Hainsworth, et al. 2012. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366:2171–2179.
11. Tang, J. Y., J. M. Mackay-Wiggan, M. Aszterbaum, R. L. Yauch, J. Lindgren, K. Chang, et al. 2012. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366:2180–2188.
12. Cirrone, F., and C. S. Harris. 2012. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma clinical therapeutics. Clin. Ther. 34:2039–2050.
13. Rodon, J., H. A. Tawbi, A. L. Thomas, R. G. Stoller, C. P. Tutschki, J. Baselga, et al. 2014. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LED225) in patients with advanced solid tumors. Clin. Cancer Res. 20:1900–1999.
14. Bendell, J., G. Weiss, J. Infante, R. Ramanathan, S. Jones, R. Korn, et al. 2012. 594 A phase I dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of LY2940680, an oral Smo inhibitor. Eur. J. Cancer 48:182.
15. Amakye, D., Z. Jagani, and M. Dorsch. 2013. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19:1410–1422.
16. Hall, J. M. H., M. L. Bell, and T. E. Fingerla. 2003. Disruption of sonic hedgehog signaling alters growth and patterning of lingual taste papillae. Dev. Biol. 255:263–277.
17. Liu, H. X., D. K. MacCallum, C. Edwards, W. Gaffield, and C. M. Mistretta. 2004. Sonic hedgehog exerts distinct, stage-specific effects on tongue and taste papilla development. Dev. Biol. 276:280–300.
18. Liu, H. X., A. Ermilov, M. Grachtchouk, L. Li, D. L. Gumucio, A. A. Dlugosz, et al. 2013. Multiple Shh signaling centers participate in fungiform papilla and taste bud formation and maintenance. Dev. Biol. 382:82–97.

19. Chandrashekar, J., M. A. Hoon, N. J. Ryba, and C. S. Zuker. 2006. The receptors and cells for mammalian taste. Nature 444:288–294.

20. Roper, S. D. 2006. Cell communication in taste buds. Cell. Mol. Life Sci. 63:1494–1500.

21. Beidler, L. M., and R. L. Smallman. 1965. Renewal of cells within taste buds. J. Cell Biol. 27:263–272.

22. Farbman, A. I. 1980. Renewal of taste bud cells in rat circumvallate papillae. Cell Tissue Kinet. 13:349–357.

23. Vandenbeuch, A., T. R. Clapp, and S. C. Kinnamon. 2008. Amiloride-sensitive channels in type I fungiform taste cells in mouse. BMC Neurosci. 9:1.

24. Zhang, Y., M. A. Hoon, J. Chandrashekar, K. L. Mueller, B. Cook, D. Wu, et al. 2003. Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways. Cell 112:293–301.

25. Chaudhari, N., and S. D. Roper. 2010. The cell biology of taste. J. Cell Biol. 190:285–296.

26. Yee, C. L., R. Yang, B. Böttger, T. E. Finger, and J. C. Kinnamon. 2001. “Type III” cells of rat taste buds: immunohistochemical and ultrastructural studies of neuron-specific enolase, protein gene product 9.5, and serotonin. J. Comp. Neurol. 440:97–108.

27. Huang, Y. A., Y. Maruyama, R. Stimac, and S. D. Roper. 2008. Presynaptic (Type III) cells in mouse taste buds sense sour (acid) taste. J. Physiol. 586:2903–2912.

28. Miura, H., Y. Kusakabe, and S. Harada. 2006. Cell lineage and differentiation in taste buds. Arch. Histol. Cytol. 69:209–225.

29. Martin, B., S. Maudsley, C. M. White, and J. M. Egan. 2009. Hormones in the naso-oropharynx: endocrine modulation of taste and smell. Trends Endocrinol. Metab. 20:163–170.

30. Elson, A. E. T., C. D. Dotson, J. M. Egan, and S. D. Munger. 2010. Glucagon signaling modulates sweet taste responsiveness. FASEB J. 24:3960–3969.

31. Shin, Y. K., B. Martin, W. Kim, C. M. White, S. Ji, Y. Sun, et al. 2010. Ghrelin is produced in taste cells and ghrelin receptor null mice show reduced taste sensitivity to salty (NaCl) and sour (citric acid) tastants. PLoS ONE 5:e12729.

32. Shin, Y. K., and J. M. Egan. 2010. Roles of hormones in taste signaling. Results Probl. Cell Differ. 52:115–137.

33. Mistretta, C. M., H. X. Liu, W. Gaffield, and D. K. MacCallum. 2003. Cyclopamine and jervine in embryonic rat tongue cultures demonstrate a role for Shh signaling in taste papilla development and patterning: fungiform papillae double in number and form in novel location in dorsal lingual epithelium. Dev. Biol. 254:1–18.

34. Wong, H., B. Alicke, K. A. West, P. Pacheco, H. La, T. Januario, et al. 2011. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical model of mutational and ligand-dependent hedgehog pathway activation. Clin. Cancer Res. 17:4682–4692.

35. Zukerman, S., J. I. Glendinning, R. F. Margolskee, and A. Sclafani. 2009. T1R3 taste receptor is critical for sucrose but not Polycose taste. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296:R866–R876.

36. Cai, H., W. N. Cong, C. M. Daimon, R. Wang, M. H. Tschöp, J. Sevigny, et al. 2013. Altered lipid and salt taste responsivity in ghrelin and GOAT null mice. PLoS ONE 8:e76553.

37. Shin, Y. K., W. N. Cong, H. Cai, W. Kim, S. Maudsley, J. M. Egan, et al. 2012. Age-related changes in mouse taste bud morphology, hormone expression, and taste responsivity. J. Gerontol. A Biol. Sci. Med. Sci. 67:336–344.

38. Miura, H., H. Kato, Y. Kusakabe, M. Tagami, J. Miura-Ohnuma, Y. Ninomiya, et al. 2004. A strong nerve dependence of sonic hedgehog expression in basal cells in mouse taste bud and an autonomous transcriptional control of genes in differentiated taste cells. Chem. Senses 29:823–831.

39. Sullivan, J. M., A. A. Borecki, and S. Oleskevich. 2010. Stem and progenitor cell compartments within adult mouse taste buds. Eur. J. Neurosci. 31:1549–1560.

40. Wong, G. T., K. S. Gannon, and R. F. Margolskee. 1996. Transduction of bitter and sweet taste by gustducin. Nature 381:796–800.

41. Margolskee, R. F. 2002. Molecular mechanisms of bitter and sweet taste transduction. J. Biol. Chem. 277:1–4.

42. He, W., K. Yasumatsu, V. Varadarajan, A. Yamada, J. Lem, Y. Ninomiya, et al. 2004. Umami taste responses are mediated by alpha-transducin and alpha-gustducin. J. Neurosci. 24:7674–7680.

43. Ruiz, C. J., K. Wray, E. Delay, R. F. Margolskee, and S. C. Kinnamon. 2003. Behavioral evidence for a role of alpha-gustducin in glutamate taste. Chem. Senses 28:573–579.

44. Kinnamon, S. C. 2012. Taste receptor signaling—from tongues to lungs. Acta Physiol. (Oxf). 204:158–168.

45. Damak, S., M. Rong, K. Yasumatsu, Z. Kokrashvili, V. Varadarajan, S. Zou, et al. 2003. Detection of sweet and umami taste in the absence of taste receptor T1r3. Science 301:850–853.

46. Shin, Y. K., B. Martin, E. Golden, C. D. Dotson, S. Maudsley, W. Kim, et al. 2008. Modulation of taste sensitivity by GLP-1 signaling. J. Neurochem. 106:455–463.

47. Yee, K. K., Y. Li, K. M. Redding, K. Iwatsuki, R. F. Margolskee, and P. Jiang. 2013. Lgr5-EGFP marks taste bud stem/progenitor cells in posterior tongue. Stem Cells 31:992–1000.